The easing of US-China trade tensions is expected to have a minimal impact on Riverstone, considering the group’s low exposure to generic gloves.
That said, we raise our risk premium assumptions to account for the higher risks associated with the easing trade tensions. Riverstone’s growth outlook is intact, premised on the recovery of global semiconductor sales and its differentiated exposure within the healthcare specialty gloves industry, which commands better profits than generic gloves.
Narrowing ASP gap of China vs Malaysia gloves.
- Read this at SGinvestors.io -
- Read this at SGinvestors.io -
For 2026, China’s ASPs could reach as high as US$31.50 (taking into account the 100% tariffs imposed during the Biden administration). In other words, Malaysia could remain competitive in 2026, if the 100% tariffs remain in place.
Our view.
Read more at SGinvestors.io.
Above is an excerpt from a report by RHB Securities Research. Clients of RHB may be the first to access the full PDF report @ https://www.rhbtradesmart.com/.
